Publication|Articles|January 10, 2024

DSCSA is Delayed, Now What?

Despite the recent enforcement delay of the Drug Supply Chain Security Act (DSCSA) until November 27, 2024, this white paper serves as an invaluable guide for pharmacies navigating the intricacies of DSCSA compliance.

This white paper aims to delve into the challenges pharmacies will encounter, the critical need to act now and sustain compliance efforts and pragmatic strategies to propel pharmacies forward despite the regulatory delays.

The DSCSA is not merely a compliance checkbox. It’s a transformative
initiative that demands a seamless integration of technology, processes and staff training.

Complete the form below to learn more.

DSCSA is Delayed, Now What?

Related Content

Creating Capacity for Care: How Technology is Supporting Community Pharmacies

Building Financial Clarity to Sustain Community Pharmacy Care

How to Open a Pharmacy: 10 Crucial Steps to Consider

Inside the Pharmacy Switch Crisis: What We Learned and Where Pharmacy Goes Next

The Hidden Cost of Inconsistent Procurement Practices Across Multi-Location Pharmacies

Latest CME

Identifying and Personalizing Iron Deficiency Anemia Treatment in Patients With Cancer

Managing Iron Replacement Therapies for Patients With Inflammatory Bowel Disease

Exploring ATTR Phenotypes and Identifying Appropriate Opportunities for Pharmacists to Intervene

The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmacist Credit)

The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmacy Technician Credit)

Iron Deficiency Anemia Treatment Considerations in Women’s Health

The Changing Paradigm in Pain Management and Supporting Access to Novel Therapies

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

Personalizing Treatment in Relapsed/Refractory Multiple Myeloma: The Evolving Role of Antibody-Drug Conjugates and Bispecific Antibodies

Advances in Castration-Sensitive Prostate Cancer: A Pharmacist's Approach to Optimize Novel Antiandrogen Therapies

Adapting to Advances in EGFR-Positive Non-Small Cell Lung Cancer Treatment: Critical Insights for Oncology Pharmacists

Securing the Supply Chain: The Pharmacists’ Role in DSCSA Compliance

Expanding the Role of Long-Acting Injectables in Optimizing Schizophrenia Management

VMAT2 Inhibitors for Long-Term Success in Tardive Dyskinesia

Shifting Perspectives in Treatment-Resistant Depression: Novel Therapies and Patient-Centered Care

Navigating Adverse Effects in HR+/HER2-Negative Metastatic Breast Cancer: Tailored Management Plans and Pharmacist Interventions for Improved Outcomes

Bridging Knowledge Gaps in HR+/HER2– Early-Stage Breast Cancer

Optimizing Therapy in HR+/HER2-Negative Metastatic Breast Cancer: Navigating Novel Treatments and Personalized Care

Optimizing HER2-Directed Therapy in Metastatic Breast Cancer: From HER2-Positive to HER2-Ultralow

Shaping the Future of Generalized Myasthenia Gravis Management: A Focus on Novel Treatment Approaches

Expert Insights on the Horizon of HER2-Directed Therapy

Breaking Barriers in Asthma Care: Exploring the Role of Type 2 Inflammation and Biologic Therapies

Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

From Flares to Freedom: Navigating the Journey of Patients With Chronic Spontaneous Urticaria With Next-Generation Therapies

Chronic Obstructive Pulmonary Disease and Inflammation: Practical Approaches to Integrating Biologic Therapy

Understanding Type 2 Inflammation and Its Role Across Various Immune-Related Diseases

Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Addressing the Burden of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: The Pharmacist's Contribution to Patient Care

Updated Guidance and Managed Care Strategies to Optimize Care in EGFR Mutated NSCLC

Payment for Pharmacist Services: 2025 Update

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Trending on Drug Topics

FDA Committee Votes Unanimously to Recommend mRNA Flu Vaccine

Metformin Cuts Long COVID Risk by Half in New ACTIV-6 Trial Results

How Will Emerging AI Impact the Pharmacy Benefit Manager Space?

McKesson Partners with Pharmacies to Grow, Navigate Challenges

Q&A: PBMs’ Adoption of AI Raises Efficiency Hopes, Ethical Concerns